<DOC>
	<DOCNO>NCT02229071</DOCNO>
	<brief_summary>This phase IB study donafenib , oral multikinase inhibitor target Raf kinase receptor tyrosine kinase , assess toxicity , efficacy pharmacokinetics patient wiht advanced hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Safety Efficacy Donafenib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Eligibility Criteria : - 18 -70 year old ; - Patients measurable , histologically proven , inoperable HCC ; - Child-Pugh ( CP ) score A ; - Eastern Cooperative Oncology Group ( ECOG ) performance status score 2 less . - Patients receive prior systemic treatment HCC 4 week ; - Patients receive operate 3 month ; - Patients receive TACE 4 week ; - Life expectancy least 3 month ; - Adequate hepatic renal function ; - Adequate hematologic function ( platelet count , ≥70×109per liter ; hemoglobin ≥8.5 g per deciliter ) ; - Prothrombin time international normalized ratio≤2 ; prothrombin time ≤16 second ; APTT≤43s ; TT≤21s . Exclusion Criteria : - Patients prior treatment sorafenib ; - CNS involvement . Method : - open-label , randomize , multiceters study ; - 2 dose cohort : 200mg bid 300mg bid ; - Patients advanced HCC ( inoperable ) Child-Pugh ( CP ) A , randomize , receive continuous donafenib either 200mg bid 300mg bid 4 week cycle ; - Sample size:106 patient ( 53 patient dose cohort ) . Endpoints : - Safety : toxicity assess accord CTCAE 3.0 ; - TTP : Tumor response assess every two cycle use RECISIT1.1 criterion ; - Donafenib pharmacokinetics measure plasma sample .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>18 70 year old Patients measurable , histologically proven , inoperable HCC ChildPugh ( CP ) score A Eastern Cooperative Oncology Group ( ECOG ) performance status score 2 less . Patients receive prior systemic treatment HCC 4 week Patients receive operate 3 month Patients receive TACE 4 week Life expectancy least 3 month Adequate hepatic renal function Adequate hematologic function ( platelet count , ≥70×109per liter ; hemoglobin ≥8.5 g per deciliter ) Prothrombin time international normalized ratio≤2 ; prothrombin time ≤16 second ; APTT≤43s ; TT≤21s . Patients prior treatment sorafenib CNS involvement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Donafenib</keyword>
	<keyword>HCC</keyword>
	<keyword>Advanced</keyword>
	<keyword>inoperable</keyword>
	<keyword>Phase 1B</keyword>
</DOC>